Journal article icon

Journal article

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

Abstract:

Objective To evaluate efficacy and safety of guselkumab, an anti-interleukin-23p19-subunit antibody, in patients with psoriatic arthritis (PsA) with prior inadequate response (IR) to tumour necrosis factor inhibitors (TNFi).

Methods Adults with active PsA (≥3 swollen and ≥3 tender joints) who discontinued ≤2 TNFi due to IR (lack of efficacy or intolerance) were randomised (2:1) to subcutaneous guselkumab 100 mg or placebo at week 0, week 4, then e...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1136/annrheumdis-2021-220991

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Botnar Research Centre
Role:
Author
ORCID:
0000-0002-4756-663X
Publisher:
BMJ Publishing Group
Journal:
Annals of the Rheumatic Diseases More from this journal
Volume:
81
Issue:
3
Pages:
359-369
Publication date:
2021-11-24
Acceptance date:
2021-10-20
DOI:
EISSN:
1468-2060
ISSN:
0003-4967
Language:
English
Keywords:
Pubs id:
1205634
Local pid:
pubs:1205634
Deposit date:
2021-10-22

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP